Skip to main content
Fig. 5 | Molecular Cancer

Fig. 5

From: Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma

Fig. 5

PD1+ EVs bind nivolumab. A Scatter plots with median of the percentage of PD-L1+ and PD1+ EVs in plasma of responders (n = 38) and non-responders (n = 33) (Mann Whitney t test **p < 0.001). B Dot plots of the NRES1 EVs resuspended in 1x PBS and positive for PD1 utilising the commercial anti-PD1 (CD279) by eBiosciences (Thermos Fisher) in green and the fluo-nivolumab in blue. C Dot plots of the NRES1 EVs resuspended in plasma of healthy donors and positive for PD1 utilising the commercial anti-CD279 in green and the fluo-nivolumab in blue

Back to article page

Molecular Cancer

ISSN: 1476-4598